These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17479486)

  • 21. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
    Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
    Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
    van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
    Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
    Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
    Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How paraproteins can affect laboratory assays: spurious results and biological effects.
    King RI; Florkowski CM
    Pathology; 2010; 42(5):397-401. PubMed ID: 20632813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism.
    Watts GF; Chan DC
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1892-5. PubMed ID: 18946055
    [No Abstract]   [Full Text] [Related]  

  • 26. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
    Santos-Gallego CG; Ibanez B; Badimon JJ
    Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capillary zone electrophoresis compared with agarose gel and immunofixation electrophoresis.
    Smalley DL; Mayer RP; Bugg MF
    Am J Clin Pathol; 2000 Sep; 114(3):487-8. PubMed ID: 10989651
    [No Abstract]   [Full Text] [Related]  

  • 28. HDL: still a target for new therapies?
    Nicholls SJ
    Curr Opin Investig Drugs; 2008 Sep; 9(9):950-6. PubMed ID: 18729001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDL-cholesterol modulation and its impact on the management of cardiovascular risk.
    Ferns G; Keti V
    Ann Clin Biochem; 2008 Mar; 45(Pt 2):122-8. PubMed ID: 18325173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Reverse cholesterol transport processes and their role in artherosclerosis regression].
    Chachaj A; Drozdz K; Szuba A
    Postepy Biochem; 2008; 54(3):301-7. PubMed ID: 19112829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
    Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
    J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of immunofixation in the diagnosis of paraproteinemias].
    Storch H; Puschkarew I; Müller-Molenar L
    Z Med Lab Diagn; 1980; 21(3):134-9. PubMed ID: 7001783
    [No Abstract]   [Full Text] [Related]  

  • 33. HDL kinetics, fish oils and diabetes.
    Barrett PH; Watts GF
    Atherosclerosis; 2001 Nov; 159(1):243-4. PubMed ID: 11689229
    [No Abstract]   [Full Text] [Related]  

  • 34. HDL cholesterol, Part II. How to get more of a good thing.
    Harv Mens Health Watch; 2007 Sep; 12(2):1-4. PubMed ID: 18217261
    [No Abstract]   [Full Text] [Related]  

  • 35. Incidental diagnosis of CML in a patient with anemia and IgG lamda monoclonal protein in blood.
    Shani D; Malik A
    Ann Hematol; 2009 Oct; 88(10):1041. PubMed ID: 19283382
    [No Abstract]   [Full Text] [Related]  

  • 36. New HDL-cholesterol reagent formulation reduces interference from samples with abnormal proteins.
    Hoefner DM
    Clin Chim Acta; 2006 Dec; 374(1-2):142-4. PubMed ID: 16701600
    [No Abstract]   [Full Text] [Related]  

  • 37. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency.
    Vaessen SF; Veldman RJ; Comijn EM; Snapper J; Sierts JA; van den Oever K; Beattie SG; Twisk J; Kuivenhoven JA
    J Gene Med; 2009 Aug; 11(8):697-707. PubMed ID: 19431216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo.
    de Haan W; Out R; Berbée JF; van der Hoogt CC; van Dijk KW; van Berkel TJ; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Biochem Biophys Res Commun; 2008 Dec; 377(4):1294-8. PubMed ID: 18992221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homocysteine increases the risk associated with hyperlipidaemia.
    Daly C; Fitzgerald AP; O'Callaghan P; Collins P; Cooney MT; Graham IM;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):150-5. PubMed ID: 19276985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.